Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Pfizer | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Pfizer

Biopharma revenues up 11% in the quarter to $10.0 billion; generic competition impacts Upjohn revenues.

By: Contract Pharma

Contract Pharma Staff

Pfizer
1Q Revenues: $12.0 billion (-8%)
1Q Earnings: $3.4 billion (-12%)
Comments: Biopharma revenues were up 11% to $10.0 billion. Eliquis sales were up 29% to $1.3 billion in the quarter. Vyndaqel sales were $231 million in the quarter compared to $41 million in 1Q19. Ibrance sales were up 10% to $1.2 billion. Prevenar 13 sales were down 2% to $1.5 billion. Inlyta sales were $169 million in the quarter compared to $73 million in 1Q19. Xeljanz sales were up 7% to $451 million. Xtandi sales were $209 million, up 25%. Enbrel sales (Outside the U.S. and Canada) were $347 million, down 23%. Upjohn sales were down 37% to $2.0 billion primarily due to significant volume declines for Lyrica in the U.S. due to multi-source generic competition. Upjohn revenues in China declined 41% operationally, driven by declines from Lipitor and Norvasc. Beginning in 2020, Upjohn began managing Pfizer’s Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan. Acquisition of Pfizer’s Consumer Healthcare business by the GSK Consumer Healthcare joint venture (JV) was completed during 2019, impacting financial results.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters